Radiometer logo

Transcutaneous oxygen (tcpO2) measurement in the management of chronic limb threatening ischemia

  • Download article as pdf
    Transcutaneous oxygen (tcpO2) measurement in the management of chronic limb threatening ischemia Sign up to download the article

    Contact Info

    By submitting this form, I acknowledge that I have reviewed and understood the data privacy notice.

    All fields must be filled!

Transcutaneous oxygen (tcpO2) measurement in the management of chronic limb threatening ischemia

An increasing number of patients around the globe suffer from chronic limb-threatening ischemia (CLTI) also known as Chronic Limb Ischemia (CLI), which is the end-stage of peripheral artery disease (PAD) [1]. CLTI is associated with high mortality, delayed wound healing, major limb amputation, pain, and diminished quality of life [1].

CLTI is more common in diabetics, people with cardiovascular disease, hyperlipidemia, smokers and males, and the incidence increases with age [1].

CLTI leads to a substantial economic burden due to surgery and the costs of rehabilitation, medicine, nursing homes, and internal medicine [2]

Diagnosis of CLTI in current guidelines

The Global Vascular Guidelines recommend ankle pressure (AP) and ankle-brachial index (ABI) as the first line screening for CLTI [1]. Transcutaneous oximetry is recommended as an alternative method for diagnosis [1].

The Society of Vascular Surgery (SVS) has created a risk stratification system that is based on three major factors that impact amputation risk and clinical management: wound, ischemia, and foot infection (WIfI) (Table 1) [3]. The WIfI classification recommends tcpO2 or toe pressure (TP) over ABI in diabetics and the elderly [4].

Table 1. WIfI classification


Diagnosis of CLTI in diabetic patients

In patients with calcified vessels the AP and ABI can be falsely elevated due to incompressible vessels, which can lead to an overestimation of the AP and ABI [3]. This is common in diabetics, where 30 to 40% of patients are estimated to have calcified vessels [3]. In these instances, transcutaneous oximetry (tcpO2) might be preferable to AP and ABI [4]. A recent systematic review by the International Working Group of the Diabetic Foot (IWGDF) of 15 studies published between 1980 and 2018, covering 6800 patients suffering from diabetes and foot ulcerations, showed that low ABI, AP, TP and transcutaneous oximetry (tcpO2) was useful to predict the likelihood of amputation [5].

However, ABI values were not useful to predict the likelihood of wound healing – an ABI can present normal values due to calcified vessels. Here the authors conclude that using tcpO2, toe pressure or skin perfusion pressure (SPP) is recommendable [5]. Hence IWGDF has three important recommendations in relation to patients with PAD, CLTI, and/or diabetic foot (Table 2) [4].

  • Perform at least one of the following bedside tests in a patient with a diabetic foot ulcer and peripheral artery disease, any of which increases the pre-test probability of healing by at least 25%; a skin perfusion pressure ≥40 mmHg, a toe pressure ≥30 mmHg; or a transcutaneous oxygen pressure (tcpO2) ≥25 mmHg.

  • Use the WIfI (wound/ischemia/foot infection) classification system to stratify amputation risk and revascularization benefit in a patient with a diabetic foot ulcer and peripheral artery disease.

  • Always consider urgent vascular imaging, and revascularization, in a patient with a diabetic foot ulcer and an ankle pressure<50 mmHg, ABI<0.5, a toe pressure <30 mmHg or a tcpO2<25 mmHg.

Table 2. Recommendations from IWGDF

tcpO2 and relation to clinical outcomes in CLTI

A meta-analysis by Arsenault and colleagues, including 31 studies with over 1800 patients, showed that values of transcutaneous oxygen predicted risk of healing complications and amputation. A value of transcutaneous oxygen of less than 40 mmHg resulted in a 24% increased risk of healing complication, and this risk increased with lower tcpO2 values [6].

Two studies published study by Fagher and colleagues showed that tcpO2 is an independent prognostic marker for 1-year mortality in diabetes patients with foot ulcers and that patients with abnormal ABI and tcpO2 < 30 mmHg had more than twice as high 3-year mortality compared to patients with normal ABI and tcpO2 [7, 8].

A cohort study by Salaun et al, of patients hospitalized for peripheral arterial disease, enrolled 556 patients with CLTI [9]. Major amputation rate was compared according to initial ankle pressure (AP), systolic toe pressure (STP), and forefoot tcpO2. AP failed to identify 42% of patients with CLTI. The authors conclude that systolic toe pressure <30 mmHg or tcpO2 <10 mmHg are the best predictive thresholds for major amputation, and that AP should not be used in the definition of a patient with CLTI [9].

Other applications of tcpO2

Pardo and colleagues compared tcpO2 to ABI in patients undergoing peripheral transluminal angioplasty (PTA) to treat CLTI before, during and after the procedure [10]. ABI could not be determined in 15% of patients, whereas it was possible to measure tcpO2 in all patients.

It was also possible to measure tcpO2 perioperatively - during the procedure - and the tcpO2 values shoved variations during the procedure that corresponded with revascularization.

After the procedure, tcpO2 increased steadily over the course of 8 weeks, even if the ABI did not change, suggesting “the usefulness of determining tcpO2 after PTA as a valuation technique of revascularization achieved after the radiological procedure”.

A small study by Cuen-Ojeda et al., showed that tcpO2 was significantly lower in patients with severe post-thrombotic syndrome compared to non-severe post-thrombotic syndrome and healthy controls, and suggest that tcpO2 might be useful in determining wound healing potential for this condition [11].

Xue and colleagues showed that transcutaneous oxygen and carbon dioxide (tcpCO2) differed significantly between patients at high and low risk for pressure ulcers, and that change in tcpCO2 and tcpO2 from lateral to supine position was higher in high-risk compared to low-risk patients [12]. The authors hypothesize that tcpO2 and tcpCO2 can be used as an objective scientific measurement to evaluate the risk of pressure ulcers.


The incidence of CLTI is increasing around the world and is associated with substantial morbidity, mortality, and health care costs. Transcutaneous monitoring of oxygen (tcpCO2) provides non-invasive monitoring of the oxygen tension of the skin and hence the microvascular function. tcpCO2 is correlated to wound healing prognosis and long-term morbidity in CLTI and diabetic wounds and has potential applications within several areas of wound care and wound prevention.


1.Conte MS, Bradbury AW, Kolh P et al. Global Vascular Guidelines on the Management of Chronic Limb-Threatening Ischemia. European journal of vascular and endovascular surgery: the official journal of the European Society for Vascular Surgery 2019; 58, 1S: S1-S109.e33.
2.Raghav A, Khan ZA, Labala RK, Ahmad J, Noor S, Mishra BK. Financial burden of diabetic foot ulcers to world: A progressive topic to discuss always. Therapeutic advances in endocrinology and metabolism 2018; 9, 1: 29–31.
3.Mills JL, Conte MS, Armstrong DG et al. The Society for Vascular Surgery Lower Extremity Threatened Limb Classification System: Risk stratification based on wound, ischemia, and foot infection (WIfI). Journal of vascular surgery 2014; 59, 1: 220-34.e1-2.
4.Hinchliffe RJ, Forsythe RO, Apelqvist J et al. Guidelines on diagnosis, prognosis, and management of peripheral artery disease in patients with foot ulcers and diabetes (IWGDF 2019 update). Diabetes/metabolism research and reviews 2020; 36 Suppl 1: e3276.
5.Forsythe RO, Apelqvist J, Boyko EJ et al. Performance of prognostic markers in the prediction of wound healing or amputation among patients with foot ulcers in diabetes: A systematic review. Diabetes/metabolism research and reviews 2020; 36 Suppl 1: e3278.
6.Arsenault KA, Al-Otaibi A, Devereaux PJ, Thorlund K, Tittley JG, Whitlock RP. The use of transcutaneous oximetry to predict healing complications of lower limb amputations: A systematic review and meta-analysis. European journal of vascular and endovascular surgery: the official journal of the European Society for Vascular Surgery 2012; 43, 3: 329–36.
7.Fagher K, Katzman P, Löndahl M. Transcutaneous oxygen pressure as a predictor for short-term survival in patients with type 2 diabetes and foot ulcers: A comparison with ankle-brachial index and toe blood pressure. Acta diabetologica 2018; 55, 8: 781–88.
8.Fagher K, Löndahl M. The combined impact of ankle-brachial index and transcutaneous oxygen pressure on mortality in patients with type 2 diabetes and foot ulcers. Acta diabetologica 2021; 58, 10: 1359–65.
9.Salaun P, Desormais I, Lapébie F-X et al. Comparison of Ankle Pressure, Systolic Toe Pressure, and Transcutaneous Oxygen Pressure to Predict Major Amputation After 1 Year in the COPART Cohort. Angiology 2019; 70, 3: 229–36.
10.Pardo M, Alcaraz M, Bernal FL, Felices JM, Achel GD, Canteras M. Transcutaneous oxygen tension measurements following peripheral transluminal angioplasty procedure has more specificity and sensitivity than ankle brachial index. The British journal of radiology 2015; 88, 1046: 20140571.
11.Cuen-Ojeda C, Anaya-Ayala JE, Laparra-Escareno H et al. Measurement of transcutaneous oxygen pressure in patients with post-thrombotic syndrome: Findings and possible clinical applications. Vascular 2020; 28, 2: 172–76.
12.Xue M, Wang D, Zhang Z et al. Demonstrating the Potential of Using Transcutaneous Oxygen and Carbon Dioxide Tensions to Assess the Risk of Pressure Injuries. International journal of biological sciences 2018; 14, 11: 1466–71.

MAPSSS-000612 R3

Cookies are used on this website

Use of cookies
Confirm your account with Radiometer

Please enter a valid email

By submitting your e-mail you agree to the data policy notice
Radiometer is using Microsoft Azure Active Directory to authenticate customer access. If you are already registered you will be taken to Microsoft AD to sign in using your Microsoft AD credentials.
You are already registered
Radiometer is using Microsoft Azure AD to authenticate customer access. If you are already registered you will be taken to AZURE to sign in using your AZURE credentials.
Thank you

We will be sending an e-mail invitation to you shortly to sign in using Microsoft Azure AD.

Radiometer is using Microsoft Azure AD to authenticate customer access.

It seems that your e-mail is not registered with us

Radiometer is using Microsoft Azure AD to authenticate customer access. If your e-mail is not registered with us please click CONTINUE and we will guide you through the sign-in process.
We have previously sent an invitation by e-mail

Please click "Get started" in the e-mail to complete the registration process

Radiometer is using Microsoft Azure AD to authenticate customer access.

We were not able to process your request due to a communication error


It seems this account has not been given access to the portal

Radiometer is using Microsoft AZURE Active Directory to authenticate users

Radiometer uses Azure AD to provide our customers and partners secure access to documents, resources, and other services on our customer portal.

If your organization is already using Azure AD you can use the same credentials to access Radiometer's customer portal.

Key benefits

  • Allow the use of existing Active Directory credentials
  • Single-sign on experience
  • Use same credentials to access future services

Request access

You will receive an invitation to access our services via e-mail when your request has been approved.

When you accept the invitation, and your organization is already using AZURE AD, you can use the same credentials to access Radiometer's customer portal. Otherwise, a one-time password will be sent via e-mail to sign in.

Effective Date January 20th, 2023 (last updated January 20th, 2023)


Radiometer values your privacy and the protection of your personal data. This policy (“Policy”) explains how Radiometer its affiliates, subsidiaries or related companies, a full list of which can be located here (together, “Radiometer”, “our”, “us”, or “we”), collects, uses, shares, transfers and processes data collected from or about you.

Personal Data” is any information that can be used to directly or indirectly identify an individual or that can be reasonably expected to link to an individual. This can include items such as name, address, telephone number, credit card details, email address, ID number, Internet Protocol (“IP”) address of an electronic device used by an individual, or other identifying code (even absent of other identifying information). Statistical and non-identifiable metric data are not considered Personal Data.

The Radiometer subsidiary, affiliate or related company with which you interact is, where applicable, the data controller (or equivalent under applicable law) responsible for the processing of your Personal Data. You can find a list of the relevant legal entities that act as data controllers in Appendix 1 to this Policy.


This Policy describes the types of Personal Data that we may collect, process or disclose about you and how you may govern this processing by exercising applicable legal rights. This Policy applies to both online and offline information collection, including your use of websites or subdomains operated by us, any mobile applications, when we provide products and/or services to you or notify you about prospective items of interest and in other situations where you interact with us in-person, by telephone or by mail where this Policy is posted or referenced.

There may be occasion where you have been provided with a circumstance-specific privacy notice that is separate from this policy, such as privacy notices for specific activities such as Recruitment. To the extent you were provided with a different notice, those notices apply and govern our interactions with you. If you provide Personal Data about parties other than yourself, you are responsible for ensuring their knowledge of how we will process their personal data, and, where applicable, obtaining any necessary consents required in advance.

We are committed to processing Personal Data in accordance with applicable laws. Please note that if you do not wish to provide your Personal Data to us, some products and/or services may become unavailable to you. Your use of any or all these platforms indicates you have been notified of our collection, use, transfer, and disclosure of your information as described in this Policy to the extent permitted by applicable law.

Read more